Novo Nordisk A/S $NVO Shares Sold by TIAA Trust National Association

TIAA Trust National Association lessened its position in shares of Novo Nordisk A/S (NYSE:NVO) by 95.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,141 shares of the company’s stock after selling 216,234 shares during the period. TIAA Trust National Association’s holdings in Novo Nordisk A/S were worth $618,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of NVO. Diversify Wealth Management LLC lifted its position in shares of Novo Nordisk A/S by 4.7% during the 3rd quarter. Diversify Wealth Management LLC now owns 24,830 shares of the company’s stock worth $1,378,000 after purchasing an additional 1,123 shares during the last quarter. Xponance Inc. raised its stake in Novo Nordisk A/S by 15.4% in the third quarter. Xponance Inc. now owns 3,891 shares of the company’s stock valued at $216,000 after buying an additional 519 shares in the last quarter. Integrated Advisors Network LLC lifted its holdings in Novo Nordisk A/S by 33.6% during the 3rd quarter. Integrated Advisors Network LLC now owns 16,394 shares of the company’s stock worth $910,000 after buying an additional 4,119 shares during the last quarter. Hohimer Wealth Management LLC boosted its position in shares of Novo Nordisk A/S by 240.1% during the 3rd quarter. Hohimer Wealth Management LLC now owns 28,382 shares of the company’s stock worth $1,575,000 after acquiring an additional 20,038 shares in the last quarter. Finally, Choreo LLC boosted its position in shares of Novo Nordisk A/S by 1.4% during the 3rd quarter. Choreo LLC now owns 120,236 shares of the company’s stock worth $6,672,000 after acquiring an additional 1,635 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Down 0.3%

Shares of NYSE:NVO opened at $37.50 on Monday. Novo Nordisk A/S has a 1-year low of $37.31 and a 1-year high of $91.90. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The stock has a market cap of $167.42 billion, a P/E ratio of 10.81 and a beta of 0.74. The firm has a fifty day moving average price of $52.75 and a 200 day moving average price of $52.88.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The business had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 23.63%.

Analyst Upgrades and Downgrades

NVO has been the subject of several recent analyst reports. Kepler Capital Markets cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. TD Cowen restated a “buy” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 3rd. Zacks Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, February 9th. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Finally, Morgan Stanley restated an “underweight” rating and issued a $42.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 3rd. Five analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $54.21.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.